Table 2 Strength of predictors between patient subgroups

Clavien‒Dindo > 3a

Clavien‒Dindo < 3a

IL-6 (1st)

N = 12; 189 (46; 2 746)

N = 103; 66 (9; 936)

0.804 (0.673; 0.934)

 < 0.001

IL-6 (3rd)

N = 11; 1 153 (19; 50 000)

N = 98; 19 (3; 473)

0.914 (0.817; 1.000)

 < 0.001

CRP (3rd)

N = 10; 192 (63; 420)

N = 71; 76 (14; 342)

0.869 (0.755; 0.983)

 < 0.001

Clavien‒Dindo > 2

Clavien‒Dindo < 2

IL-6 (1st)

N = 14; 145 (31; 2 746)

N = 101; 66 (9; 936)

0.751 (0.612; 0.890)

0.002

IL-6 (3rd)

N = 13; 263 (18; 50 000)

N = 96; 19 (3; 473)

0.865 (0.755; 0.976)

 < 0.001

CRP (3rd)

N = 10; 192 (63; 420)

N = 71; 76 (14; 342)

0.869 (0.755; 0.983)

 < 0.001

ICU > 5 days

ICU < 5 days

IL-6 (1st)

N = 33; 138 (32; 2 746)

N = 82; 56 (9; 419)

0.811 (0.727; 0.895)

 < 0.001

IL-6 (3rd)

N = 32; 43 (9; 50 000)

N = 77; 18 (3; 83)

0.814 (0.724; 0.904)

 < 0.001

CRP (3rd)

N = 27; 155 (32; 420)

N = 54; 62 (14; 185)

0.838 (0.742; 0.934)

 < 0.001

Hospital stay > 10 days

Hospital stay < 10 days

IL-6 (1st)

N = 30; 138 (26; 2 746)

N = 85; 65 (9; 352)

0.771 (0.669; 0.872)

 < 0.001

IL-6 (3rd)

N = 29; 61 (8; 50 000)

N = 80; 18 (3; 1 387)

0.800 (0.700; 0.899)

 < 0.001

CRP (3rd)

N = 23; 155 (32; 292)

N = 58; 73 (14; 420)

0.752 (0.631; 0.873)

 < 0.001

ATB treatment

No ATB treatment

IL-6 (1st)

N = 24; 152 (43; 2 746)

N = 91; 64 (9; 352)

0.818 (0.725; 0.912)

 < 0.001

IL-6 (3rd)

N = 23; 79 (15; 50 000)

N = 86; 18 (3; 114)

0.854 (0.766; 0.942)

 < 0.001

CRP (3rd)

N = 20; 171 (63; 420)

N = 61; 66 (14; 201)

0.879 (0.798; 0.959)

 < 0.001

Inflammatory complication

No inflammatory complication

IL-6 (1st)

N = 29; 138 (31; 2 746)

N = 86; 61 (9; 352)

0.798 (0.705; 0.890)

 < 0.001

IL-6 (3rd)

N = 28; 52 (15; 50 000)

N = 81; 18 (3; 114)

0.839 (0.758; 0.920)

 < 0.001

CRP (3rd)

N = 22; 178 (63; 420)

N = 59; 64 (14; 178)

0.904 (0.833; 0.974)

 < 0.001